Biofrontera AG

Welcome to the conference call to discuss the Q3 2021 earnings results. At our customer's request, this conference will be recorded. As a reminder, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. If any participant has difficulties hearing the conference, please press star key followed by zero on your telephone for operator assistance. May I now hand you over to Pamela Keck, head of IR, who will lead you through this conference. Please go ahead.

Thank you. Good morning, good afternoon, and welcome to BioFrontera's earnings conference call for the third quarter 2021. Yesterday, we issued a press release announcing financial results for the nine months ended September 30th, 2021. We encourage everyone to read the press release as well as the Q3 earnings report, both of which are available on our website. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that, during this call, BioFronteros management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioFrontera's press releases and all SEC filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, today, November 18, 2021. BioFrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. And with that, I would now like to turn the call over to Hermann Luegert, our CEO.

Thank you, Pamela. And thank you very much, ladies and gentlemen, for taking the time to participate in today's call. With me today is Ludwig Luther, our CFO. He will present the financial results in a second. Following that, I would like to share with you updates regarding our current regulatory and clinical development, as well as the current business performance and activities. But first now to the financial results of the first nine months of 2021. For that, I would like to hand over to Ludwig.